Cirius Therapeutics
2015
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
IPO
LATEST DEAL TYPE
(Cancelled)
$86.2M
LATEST DEAL AMOUNT
5
INVESTORS
Description
Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's insulin sensitizer is used to treat nonalcoholic steatohepatitis which is characterized by buildup of fat and inflammation in the liver, may be accompanied by fibrosis and can progress to life-threatening cirrhosis or liver cancer, enabling healthcare providers to treat patients of liver and metabolic diseases and avoid recurrence of nonalcoholic steatohepatitis.
Website
Formerly Known As
Octeta Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
- 12651 High Bluff Drive
- Suite 150
- San Diego, CA 92130
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Cirius Therapeutics’s full profile, request a free trial.
Cirius Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. IPO | 20-Dec-2019 | $86.2M | Cancelled | Clinical Trials - Phase 3 | ||
| 4. Early Stage VC (Series A3) | 10-May-2019 | 00.00 | 000.00 | 00000 | Completed | Clinical Trials - General |
| 3. Early Stage VC (Series A3) | 23-Aug-2018 | 000 | 000.00 | 00000 | Completed | Startup |
| 2. Early Stage VC (Series A2) | 10-Apr-2017 | $40M | $56.4M | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A1) | 19-May-2016 | $16.4M | $16.4M | 000.00 | Completed | Startup |
Cirius Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A2 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A1 | 17,069,451 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 17.25% |
Cirius Therapeutics Competitors (47)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tioga Pharmaceuticals | Venture Capital-Backed | San Diego, CA | 00 | 0000 | 000000 - 000 | 0000 |
| 000000000 | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 0000000000 0000000 | Venture Capital-Backed | Mont-Saint-Guibert, Belgium | 00 | 00000 | 00000000000 | 00000 |
| 00000 000000 | Venture Capital-Backed | New York, NY | 0000 | 0000000000 0 | 0000 | |
| 000000000(00000000 | Formerly VC-backed | New York, NY | 000 | 00000 | 000000 - 000 | 00000 |
Cirius Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Adams Street Partners | Fund of Funds | Minority | 000 0000 | 000000 0 | ||
| Frazier Healthcare Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Hopen Life Science Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Novo Holdings | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Renaissance Venture Capital Fund | Fund of Funds | Minority | 000 0000 | 000000 0 |
Cirius Therapeutics Executive Team (5)
1 Former Executive
You’re viewing 4 of 5 executives. Get the full list »Cirius Therapeutics Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Daniel Estes Ph.D | Frazier Healthcare Partners | Board Member | 000 0000 | |
| David Van Andel | Cirius Therapeutics | Board Member | 000 0000 | |
| Dennis Fenton Ph.D | Self | Board Member | 000 0000 | |
| Elaine Sun | Self | Board Member | 000 0000 | |
| Michael Jandernoa | Cirius Therapeutics | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 9 board members. Get the full list »